Neupro®(Restless Legs Syndrome) Europe In Europe, Neupro® (rotigotine transdermal patch) is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in adults. USA In the US, Neupro® (Rotigotine Transdermal System) is indicated for the treatment of moder...
FOR RESTLESS LEGS SYNDROME NEUPRO can help relieve the symptoms of RLS. Find helpful information and the tools you need to get started, here. RLS PATIENTS HEALTHCARE PROFESSIONALS It's important toapply the NeuproPatch correctly Take a few minutes to watch this video on how to apply the NEUPR...
Neupro(R), The Only Transdermal Patch For Restless Legs Syndrome, Now Available In The UK
Use: Treatment of moderate-to-severe primary Restless Legs Syndrome What happens if I miss a dose? If you forget to change a patch on your scheduled day, remove and replace the patch as soon as you remember. Wear the new patch until your next regular patch-changing time. Do not change ...
The other two doses, of 1 mg and 3 mg for 24 hours, are indicated for restless legs syndrome.Each patch is composed of three layers: a backing film, the drug matrix, and a protective liner. The backing film is a flexible and tan-colored material whose primary function is to offer ...
Application site reactions (ASRs) exhibited a dose-dependent relationship for all doses in patients with both Parkinson's disease and restless legs syndrome. Reactions included localized erythema, edema, or pruritus, generally limited to the patch area; although generalized skin reactions such as ...
In patients with Restless Legs Syndrome, the recommended starting dose for NEUPRO is 1 mg/24 hours. Based upon individual patient clinical response and tolerability, NEUPRO dosage may be increased weekly by 1 mg/24 hours if additional therapeutic effect is needed. The lowest effective dose is 1...
The other two doses, of 1 mg and 3 mg for 24 hours, are indicated for restless legs syndrome.Each patch is composed of three layers: a backing film, the drug matrix, and a protective liner. The backing film is a flexible and tan-colored material whose primary function is to offer ...
UCB has been developing rotigotine transdermal patch system (Neupro; SPM-962) as a treatment for RLS. This system is designed to replace levels of dopamine in the body via once-daily application of the patch, in a bid to restore proper motor functioning. The rotigotine patch has been ...
Rotigotine is a D3/D2/D1 dopamine agonist delivered through a silicone-based transdermal patch that is administered once daily. Pharmacokinetic data in humans have shown that steady-state plasma levels of rotigotine can be reached between 8 and 12 hours, and a stable drug release is maintained...